Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Skye Bioscience, Inc. (SKYE : OTC)

• Company Description    Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $0.04 Daily Weekly Monthly 20 Day Moving Average: 960,750 shares Shares Outstanding: 495.92 (millions) Market Capitalization: $19.59 (millions) Beta: 0.41 52 Week High: $0.26 52 Week Low: $0.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.83% 24.73% 12 Week 3.95% 12.79% Year To Date -24.04% -9.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11250 EL CAMINO REAL SUITE 100 - SAN DIEGO,CA 92130 USA ph: 858-410-0266 fax: - ir@skyebioscience.com http://www.skyebioscience.com

• General Corporate Information    Officers Punit Dhillon - Chief Executive Officer; Chairman Kaitlyn Arsenault - Chief Financial Officer Margaret Dalesandro - Director Jim Heppell - Director Keith Ward - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83086J101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/05/22 Share - Related Items Shares Outstanding: 495.92 Most Recent Split Date: (:1) Beta: 0.41 Market Capitalization: $19.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -194.17 12/31/21 - -180.56 09/30/21 - -223.14 ROA 03/31/22 - -109.86 12/31/21 - -105.12 09/30/21 - -119.02 Current Ratio 03/31/22 - 1.67 12/31/21 - 2.46 09/30/21 - 7.61 Quick Ratio 03/31/22 - 1.67 12/31/21 - 2.46 09/30/21 - 7.61 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.01 12/31/21 - 0.01 09/30/21 - 0.02 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.17 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 14.22

Powered by Zacks Investment Research ©